Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

GeoVax and Vivalis Sign Deal for the Biomanufacture of MVA HIV Vaccine in EB66 Cells

Potentially €4 million agreement will lead to production of clinical trials material for GeoVax at Vivalis’ facility.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »